GLP-1 receptor ligands are famous as metabolic drugs. US12115225B2 - "GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof," issued October 15, 2024 to AstraZeneca AB - uses one for something else entirely: as a delivery address for an oligonucleotide.
The inventive limitation is the repurposing of the ligand. Cells that express the GLP-1 receptor (in the pancreas, gut, and elsewhere) will take up a molecule bearing a GLP-1R ligand. The claim conjugates that ligand to a silencing oligonucleotide, so the ligand acts as a homing device that delivers the RNA cargo to GLP-1R-bearing tissue - not as a receptor agonist driving a metabolic effect.
The CPC profile makes the dual chemistry visible: A61K 47/6425 and A61K 47/65 (targeting-conjugate chemistry), A61K 31/713 (siRNA), C12N 15/111 (the oligonucleotide), with the dense C12N 2310/3xx series describing the oligonucleotide's chemical modifications. This is an oligonucleotide-delivery claim wearing a GLP-1 ligand as its targeting tag.
Why does the targeting role decide scope? Because the prior art separately holds GLP-1R ligands (as drugs) and silencing oligonucleotides. The claimed novelty is the conjugate that uses the ligand to deliver the oligonucleotide to a chosen cell population. A competitor using a different targeting moiety, or using the GLP-1 ligand as a conventional agonist, may fall outside a claim drawn to this ligand-as-delivery-vehicle construct.
For the landscape, this grant sits at the intersection of the metabolic-peptide estate and the oligonucleotide-delivery estate - a convergence that turns a well-known drug class into a delivery technology. It illustrates why freedom-to-operate analysis cannot silo by therapeutic area: a GLP-1 ligand can show up as the targeting arm of an RNA drug, pulling two previously separate IP fields into one claim.